Article

The future promise of advanced therapies in ophthalmology

Six years after the first approved gene therapy in ophthalmology, the field is seeing a flurry of activity in innovative cell and gene therapy (CGT) studies addressing high unmet needs. Here’s what could be in store for the future.

Louis Cicchini
Director, Scientific Affairs, Cell & Gene Therapy at Cencora

Fill out the form below to read more

Pardot Form

Related resources

White paper

Essential guide to post-approval regulatory lifecycle maintenance

Learn more

White paper

Best practice guide: How to effectively manage local affiliate pharmacovigilance outsourcing

Learn more

Article

CGT access: Managing risk at scale

Learn more

Connect with our cell and gene experts

Schedule some time with our cell and gene experts today. We look forward to hearing from you.